Bio-Rad cuts FY24 revenue growth view to (4%)-(2.5%) from (2.5%)-(1%)

Bio-Rad is updating its financial outlook for the full year 2024. The company currently expects its non-GAAP revenue to decline by approximately 2.5 to 4.0 percent on a currency-neutral basis compared to its previous estimate of 1.0 to 2.5 percent revenue growth. Bio-Rad also estimates a non-GAAP operating margin of about 12.0 to 13.0 percent versus the company’s prior estimate of approximately 13.5 to 14.0 percent.